MX2020010878A - Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos. - Google Patents

Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.

Info

Publication number
MX2020010878A
MX2020010878A MX2020010878A MX2020010878A MX2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A
Authority
MX
Mexico
Prior art keywords
methods
making
positive allosteric
allosteric modulator
modulator compounds
Prior art date
Application number
MX2020010878A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Toczko
Jed Hubbs
Original Assignee
Neurocycle Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocycle Therapeutics Inc filed Critical Neurocycle Therapeutics Inc
Publication of MX2020010878A publication Critical patent/MX2020010878A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Psychiatry (AREA)
MX2020010878A 2018-04-18 2019-04-17 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos. MX2020010878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659226P 2018-04-18 2018-04-18
PCT/US2019/027880 WO2019204446A1 (en) 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010878A true MX2020010878A (es) 2021-01-29

Family

ID=68239798

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010878A MX2020010878A (es) 2018-04-18 2019-04-17 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.
MX2024004400A MX2024004400A (es) 2018-04-18 2020-10-14 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004400A MX2024004400A (es) 2018-04-18 2020-10-14 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.

Country Status (14)

Country Link
US (3) US11542263B2 (https=)
EP (1) EP3781566A4 (https=)
JP (3) JP7449272B2 (https=)
KR (2) KR102799156B1 (https=)
CN (2) CN112384513A (https=)
AU (2) AU2019255282B2 (https=)
BR (1) BR112020021104A2 (https=)
CA (1) CA3096890A1 (https=)
CL (1) CL2020002663A1 (https=)
IL (1) IL278067A (https=)
MX (2) MX2020010878A (https=)
SG (1) SG11202010220QA (https=)
TW (1) TW202012402A (https=)
WO (1) WO2019204446A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
JP2022553718A (ja) * 2019-10-22 2022-12-26 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
AU2023356939A1 (en) * 2022-10-04 2025-04-10 Engrail Therapeutics, Inc. Gaba a receptor modulators and uses thereof
WO2025175214A1 (en) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Methods of treating generalized anxiety disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802343C2 (de) 1978-01-20 1982-04-22 Peter Prof. Dr.-Ing. Friderichs Latentwärmespeicher-Behälter
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) * 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2009021957A2 (en) 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
SG11201806393QA (en) * 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用

Also Published As

Publication number Publication date
JP7721712B2 (ja) 2025-08-12
AU2019255282B2 (en) 2024-08-08
WO2019204446A1 (en) 2019-10-24
SG11202010220QA (en) 2020-11-27
AU2019255282A1 (en) 2020-11-05
AU2024259803A1 (en) 2024-11-28
CN112384513A (zh) 2021-02-19
US20230139418A1 (en) 2023-05-04
EP3781566A4 (en) 2022-06-22
JP2025166011A (ja) 2025-11-05
JP2024063136A (ja) 2024-05-10
CN121135719A (zh) 2025-12-16
MX2024004400A (es) 2024-04-29
KR20210011921A (ko) 2021-02-02
KR20250057112A (ko) 2025-04-28
US20210040103A1 (en) 2021-02-11
JP7449272B2 (ja) 2024-03-13
US20250034155A1 (en) 2025-01-30
BR112020021104A2 (pt) 2021-02-23
JP2021522330A (ja) 2021-08-30
US12134619B2 (en) 2024-11-05
IL278067A (en) 2020-11-30
CA3096890A1 (en) 2019-10-24
KR102799156B1 (ko) 2025-04-21
TW202012402A (zh) 2020-04-01
CL2020002663A1 (es) 2021-06-11
EP3781566A1 (en) 2021-02-24
US11542263B2 (en) 2023-01-03

Similar Documents

Publication Publication Date Title
MX2020010878A (es) Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.
CL2020002848A1 (es) Sales de un inhibidor de fgfr.
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CL2020002866A1 (es) Compuestos de heteroaril tetracíclicos
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX2018016281A (es) Formas solidas cristalinas de inhibidor de bromodominio y extra-terminal (bet).
ECSP20029142A (es) Ligandos de psma para la formación de imágenes y endorradioterapia
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CO6311106A2 (es) Derivados novedosos del acido oleanólico con saturacion del anillo c
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
DOP2015000300A (es) Compuestos de pirimidinodiona contra estados cardíacos
AR091604A1 (es) Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR085724A1 (es) ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2020011740A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso.
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2022000980A1 (es) Compuestos moduladores alostéricos positivos de gabaa, métodos de preparación y usos de los mismos
MX2019009288A (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion.
BR112021018357A2 (pt) Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma
MX2020003832A (es) Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.
BR112022004068A2 (pt) Inibidor da magl e seu método de preparação e uso